We know that delivering a biologic to the market can be a very challenging and time sensitive process. Robust safety data, timely reporting, and rigorous attention to quality are critical factors in the successful development of a biologic from preclinical testing to product release. Charles River's global Biopharmaceutical Services (BPS) delivers client-focused solutions for the specific testing and manufacturing requirements of your biologic.
We are one comprehensive source for testing and clinical-scale manufacturing. The assays we provide range from cell characterization and process validation studies through to stability and product release testing. Manufacturing services include cell banking and storage, fill and finish, and antisera production.
Through the recent acquisition of NewLab BioQuality AG, we have expanded our global footprint with sites in both Erkrath and Cologne, Germany, which complement our existing facilities in Malvern, PA, USA; Edinburgh, UK; and Ballina, Co. Mayo, Ireland. Furthermore, in order to address the growing Asia market, we have agents located in Japan (LSG Corporation), India (Zelle Biotechnology), Korea (Sartorius Korea Biotech) and Taiwan (Life Optimal Technology, Inc.). As a result, we can now provide you with even more flexibility, experience, and expertise in multiple regulatory environments.
biopharmaceutical manufacturing services